Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTP-850 Prostate Cancer Immunotherapeutic in Biochemical Recurrence
2023-504066-39-00Phase 2Withdrawn
- Sponsor
- Barinthus Biotherapeutics
- Start
- Jun 2023
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 2 trial of ChAdOx1-PCAQ in prostate cancer (PCa), sponsored by Barinthus Biotherapeutics. Planned start Jun 2023; status: withdrawn.
02
Drugs
ChAdOx1-PCAQ
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-504066-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504066-39-00.